Seeking Alpha

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture ...

60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent “The retrograde instillation of JELMYTO for the clinical management of low-grade upper tract urothelial ...
Business Wire

Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO ® Versus Retrograde Administration

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Nasdaq

Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in ...

REN-001 delivered locally via low-dose retrograde coronary sinus infusion demonstrated robust, diffuse cardiomyocyte transduction in a large animal heart Sign up for our newsletter to get the latest ...
Yahoo

Mercury retrograde 2025: What, when it is and how it affects your zodiac sign

Mercury is officially in retrograde, and it's the last retrograde of 2025. What does that mean for your star sign, and the cosmos in general? Here's what to know. In the astronomical sense, a planet ...
Eagle-Tribune

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture ...

“The retrograde instillation of JELMYTO for the clinical management of low-grade upper tract urothelial cancer is FDA-approved and offers a safe and efficacious mode of administration, and this study ...